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Abstract MicroRNA-146a (miR-146a) has been shown to
play an important role in the regulation of inflammatory
innate immune responses, and found to be differentially
expressed in rheumatoid arthritis (RA). Through NF-jB
pathway, this molecule is able to stimulate the release of pro-
inflammatory cytokines such as TNF-a, IL-1b, and IL-17. It
has been also suggested that single-nucleotide polymor-
phisms (SNPs) in miRNA sequences may alter miRNA
expression and that miR-146a rs2910164 SNP may con-
tribute to RA development. These observations prompted us
to analyze the potential associations between the miR-146a-
3p (rs2910164, G[C) and NFkB1 (rs28362491, ins/del
ATTG) polymorphisms and miR-146a-5p expression in
patients’ sera in relation to clinical outcome of the treatment
as well as predisposition to RA. Genotyping was performed
in 111 patients and 130 healthy individuals while 16 controls
and 13 RA patients (before and after three months of therapy
with TNF-a inhibitors (TNFi)) were studied for the circu-
lating miR-146a-5p serum expression level. Patients
carrying the NFkB1 ins/ins genotype were characterized by
worse response to TNFi treatment (p = 0.023). In patients,
before TNFi therapy, expression levels ofmiR-146a-5pwere
less (0.422 ± 0.171) as compared to those detected after
three months of treatment (1.809 ± 0.658, p = 0.033) and
observed for healthy controls (5.302 ± 2.112, p = 0.048).
Moreover, patients with higher circulating miR-146a-5p
levels after three months of TNFi administration were more
frequently carrying the rs2910164-C allele (p = 0.032).
These results support the hypothesis that miR-146a might be
involved in pathogenesis of RA and imply thatmiR-146a-3p
polymorphism may be associated with miR-146a-5p levels
in serum after anti-TNF-a treatment.
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Introduction
Rheumatoid arthritis (RA) is a systemic, inflammatory
autoimmune disease primarily characterized by chronic
synovitis and progressive joint destruction. The exact cause
of RA remains unknown, however, it has been shown that
both genetic and environmental factors play a role in the
disease development (McInnes and Schett 2011). Anti-tu-
mor necrosis factor (anti-TNF) biologic agents represent a
novel approach in RA management that significantly
improved the prognosis of RA patients. Although, sub-
stantial proportion of patients do not respond to the therapy
with TNF inhibitors. The reasons of anti-TNF therapy
failure have not been established to date. The search of
biomarkers of anti-TNF agents’ efficacy is of importance to
optimize patient benefit and reduce cost of treatment.
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MicroRNAs (miRNAs, miRs) and nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-jB) are well-
known immune response and inflammation regulators.
MiRNAs are a family of single-stranded, non-coding
endogenous regulatory molecules, cleaved from double
stranded precursors, typically composed of 21–23 nucleo-
tides. They are involved in the regulation of gene
expression mainly at posttranscriptional level (Bartel
2009). It is estimated that the genes encoding the miRNA
constitute 1–5% of the genes in humans and animals. A
total of 2588 mature miRNAs were identified in humans
(Eulalio and Mano 2015). More than 30% of protein
encoding genes in human cells are regulated by miRNA
(Krol et al. 2010). A single miRNA molecule can simul-
taneously control the expression of hundreds of target
genes.
MiRNAs are known to be the target for NF-jB tran-
scriptional control and at the same time are involved in the
modulation of NF-jB signaling (Boldin and Baltimore
2012; Ghosh and Hayden 2008).
NF-jB regulates numerous pro-inflammatory cytokines,
chemokines, and adhesion molecules involved in the acti-
vation and recruitment of inflammatory modulating cells
(Ghosh and Hayden 2008). Patients with RA present con-
stitutively high serum levels of pro-inflammatory
cytokines, including TNF-a, IL-1b, IL-6 or IL-17, which
are known to be NF-jB target genes, suggesting activation
of this signaling pathway in the course of disease.
Our former studies showed that genetic variability
within genes coding for pro-inflammatory cytokines (Bo-
gunia-Kubik et al. 2015; S´wierkot et al. 2015) may play a
role in RA development and response to treatment with
TNF-a inhibitors (TNFi). It has been also documented that
acting through NF-jB pathway, some miRNAs such as
miR-146a and miR-155 may stimulate the release of pro-
inflammatory cytokines. As the inflammatory mediators,
these cytokines can induce lymphocytes, resident synovial
cells, and other inflammatory cells to produce miRNAs that
are related to disease activity of rheumatic disorders as
shown for RA patients (Chen et al. 2015).
The miR-146 acts as a negative regulator of the TLR/
NF-jB signaling pathway. It was reported that the NF-jB
activation may induce expression of the miR-146. On the
other hand, miR-146 affects the expression of TNF
receptor-associated factor 6 (TRAF6) and IL-1 receptor-
associated kinase 1 (IRAK1), that constitute key adapter
molecules involved in the Toll-like receptor (TLR)/NF-jB
pathway. MiR-146-dependent downregulation of the
TRAF6 and IRAK1 may result in inhibition of the TLR/
NF-jB signaling axis (Taganov et al. 2006). The G[C
substitution (rs2910164) at position ?60 relative to the first
nucleotide of the precursor mir-146a is a potentially
functional single-nucleotide polymorphism (SNP) within
the pre-mir-146a (5q33) gene that also occurs in the 3p
strand in mature miRNA. This SNP affects the amount of
pre- and mature miRNA-146 through disruption of
miRNA-146 processing (Jazdzewski et al. 2008). A direct
functional effect of the rs2910164 polymorphism on the
miRNA-146a capacity to inhibit its target genes (TRAF6
and IRAK1) has been also revealed (Jazdzewski et al.
2008). Taking into account that TRAF6 and IRAK1 have
been implicated in RA pathogenesis, this polymorphism
may contribute to RA development (Chatzikyriakidou et al.
2010).
There is a common insertion/deletion (–94 ins/del
ATTG) polymorphism located within the NFkB1 promoter
(rs28362491) exerting functional effects on the transcrip-
tion of the gene (Karban et al. 2004). This gene is located
on chromosome 4q24 and encodes subunits p105 and p50
kD of NF-jB. The p50 homodimer represses transcription
of pro-inflammatory cytokines and stimulates transcription
of anti-inflammatory cytokines (Cartwright et al. 2016).
The aim of the present study was to analyze potential
associations between NFkB1 (rs28362491, ins/del ATTG)
and miR-146a-3p (rs2910164, G[C) polymorphisms and
miR-146a-5p expression in patients’ sera in relation to




DNA was isolated from peripheral blood of 111 RA
patients hospitalized at the Rheumatology Clinic of the
Medical University in Wroclaw and 130 healthy indi-
viduals that served as a control group for disease
association studies. Patients and controls were geno-
typed for the miR-146a-3p (rs2910164, G[C) alleles
using a polymerase chain reaction (PCR) amplification
employing the LightSNiP assay (TIB MOLBIOL, Ber-
lin, Germany). Capillary electrophoresis or PCR
followed by restriction fragment length polymorphism
(PCR–RFLP with PflMl digestion) were employed to
study the NFkB1 (rs28362491, ins/del ATTG) alleles, as
previously described by Zhou et al. (2009) and Koc
et al. (2014), respectively. Separation of PCR products
was performed in a 50 cm 8 capillary array containing
POP-7 polymer on 3500 Genetic Analyzer (Applied
Biosystem, USA) and analyzed by GeneMapper Soft-
ware v 4.2 (Applied Biosystem, USA). Both techniques
gave the same results with 100% concordance in
duplicate samples.
S132 Arch. Immunol. Ther. Exp. (2016) 64 (Suppl 1):S131–S136
123
The study was approved by the Wroclaw Medical
University Ethics Committee and written informed consent
was obtained from all participants.
Analysis of Circulating miR-146a-5p Expression
For analysis of the miR-146a-5p expression, RNA was
isolated from sera of 13 patients (before and three months
after anti-TNF-a treatment) and 16 healthy controls with
the use of Nucleospin miRNA Plasma (MACHEREY–
NAGEL GmbH&Co.KG). Reverse transcription was con-
ducted using TaqMan MicroRNA Reverse Trascription
Kit Cat. # 4,366,596 (Applied Biosystems, Life Tech-
nologies), in accordance with the manufacture’s protocol.
The reaction was carried out in a SimpliAmpTM Thermal
Cycler (Applied Biosystems, Life Technologies) at 16 C
for 30 min, 42 C for 30 min, and 85 C for 5 min. The
product of reverse transcription was stored at –20 C until
further use.
Expression of miR-146a-5p was analyzed by Real Time
PCR. The reaction was performed on a ViiaTM 7 Real Time
PCR System (Applied Biosystems) using the TaqMan
microRNA Assay quantitate miRNAs: hsa-miR-146a-5p
Cat. # 4,427,975 primers for human miR-146a-5p and U6
together with TaqMan Universal PCR Master Mix II, no
UNG Cat. # 4,440,040 (Applied Biosystems). MiR-146a-5p
expression was normalized to U6, which was endogenous
small nuclear RNA control (TaqMan MicroRNA Assays,
Applied Biosystems). All reactions were carried out in
duplicates. The results were analyzed using the (DDCt)
calculations. The data are presented as mean ± SEM.
Statistical Analysis
All genotypes were tested for deviations from Hardy–
Weinberg equilibrium (HWE) using the v2 test. Fisher’s
exact test was used to compare the allele and genotype
frequencies between patients and controls.
The differences in miR-146a-5p serum expression levels
between the groups were tested by non-parametric two-
tailed T test or Wilcoxon matched-pairs rank test. A p value
of less than 0.05 was considered statistically significant.
Results
Distribution of the miR-146a and NFkB1 Genotypes
in Patients and Controls
We found no evidence that genotype frequencies of the two
polymorphisms examined were different from those
expected from HWE both in controls and cases. There was
no linkage disequilibrium between the studied polymor-
phisms. Genotype distributions of both SNPs were similar
between patients and controls (Table 1). Thus, neither the
rs2910164 miR-146a-3p nor the rs28362491 NFkB1 poly-
morphism was found to be associated with predisposition
to RA. Furthermore, no significant relationship was
detected for any of parameters such as: anti-cyclic citrul-
linated peptide antibodies, rheumatoid factor, C-reactive
protein and disease activity score (DAS28) (individual data
not shown).
Response to TNFi Treatment
Clinical response was evaluated according to the European
League Against Rheumatism criteria at the third month
after initiation of the TNFi therapy (Fransen and van Riel
2005).
The NFkB1 ins/del polymorphism was found to be
associated with response to the biological treatment.
Patients homozygous for the ins allele appeared to be
worse responders as compared to the del allele carriers.
The ins/ins genotype was detected in 11 out of 18 (61%) of
patients with unsuccessful outcome of the treatment and
only in 16 out of 56 (18%) of those for whom the therapy
was successful (p = 0.023; Fig. 1).
Moreover, some significant differences were observed
with respect to the expression levels of circulating miR-
146a-5p. Patients after three months of TNFi administra-
tion had higher miR-146a-5p levels in serum than those
before the treatment (4.3-fold increase; 1.809 ± 0.658 vs
0.422 ± 0.171, p = 0.033; Fig. 2a) and they were more
frequently carrying the miR-146a C allele (the gray dots on
the graph; Fig. 2b). Four out of five patients (80%) carrying
the C variant presented with increased serum levels after
Table 1 Distribution of rs2910164 miR-146a-3p and rs28362491 NFkB1 genotypes in RA patients and controls
Gene Polymorphism Genotype RA patients Controls
miR-146a-3p rs2910164 GG 72 (65%) 88 (68%)
GC 32 (29%) 36 (28%)
CC 7 (6%) 6 (4%)
NFkB1 rs28362491 ins/ins 36 (33%) 43 (34%)
ins/del 55 (50%) 69 (55%)
del/del 19 (17%) 14 (11%)
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TNFi treatment as compared to only one out of eight
(12.5%) of the GG homozygous patients (p = 0.032;
Fig. 2b). Expression was higher in controls as compared to
the patients, especially those before TNFi treatment (2.9-
fold; 5.302 ± 2.112 vs 1.809 ± 0.658, p = 0.048;
Fig. 2a). The NFkB1 ins/del polymorphism was not found
to affect the serum expression level of circulating miR-
146a.
Discussion
The results of the present study suggest that miR-146a
might play an important role in the pathogenesis of RA.
Serum expression levels of miR-146a-5p were significantly
reduced in patients as compared to healthy individuals.
Moreover, increase of miR-146a-5p expression levels was
observed in patients after three months of anti-TNF-a
therapy. This observation indicates that administration of
anti-TNF-a drugs gradually increases the miR-146-5p level
in patients’ sera, potentially up to the level observed for
healthy controls. Our data also imply that miR-146a-3p
rs2910164 polymorphism may be associated with miR-
146a-5p levels in serum after TNFi treatment, with higher
levels observed for the C allele carriers. However, this
genetic variant did not influence the predisposition to RA
or efficacy of anti-TNF-a therapy.
In line with the results of our present study, the reduced
miR-146a serum expression levels have been previously
reported by Filkova´ et al. (2014) in patients with early RA
as compared to healthy controls. Also, significantly
reduced serum levels of miRNA-146a were observed in
patients with established RA (Wang et al. 2012). Moreover,
changes of miR-146a levels in sera of RA patients before
and after anti-TNF treatment have been investigated in the
study by Castro-Villegas et al. (2015). Consistent with our
results, serum expression levels of the miR-146a were
significantly upregulated in patients following anti-TNF
therapy (Castro-Villegas et al. 2015). On the other hand,
elevated expression of the miR-146a was observed in
synovial tissues, synovial fluid monocytes, peripheral
blood-derived mononuclear cells, and serum from RA
patients (Murata et al. 2010; Pauley et al. 2008).
The previous studies documented that the miR-146a
SNP may be associated with predisposition to metabolic
syndrome development (Mehanna et al. 2015) or carcino-
genesis (Jazdzewski et al. 2008; Wojcicka et al. 2014). As
for the miR-146a SNP, some associations with pathogen-
esis of rheumatic diseases have been described especially
for patients with ankylosing spondylitis in a Han Chinese
population (Xu et al. 2015). However, this SNP has not
been reported to be associated with RA in either Asian or
Caucasian populations (Chatzikyriakidou et al. 2010; El-
Shal et al. 2013; Zhou et al. 2015; the present study).
Although, in a study of Zhou et al. (2015), a significant
association of the GG genotype with RA in females was
observed, while the CC homozygosity seemed to be cor-
related with the DAS28 score.
With respect to the NFkB1 (rs28362491, ins/del ATTG)
polymorphism, the previous studies documented that it
may affect the susceptibility to various diseases, e.g.,
cancer (Bu et al. 2007; Cartwright et al. 2016), autoim-
mune disorders including ulcerative colitis (Karban et al.
Fig. 1 Relationship between the NFkB1 polymorphism and response
to treatment in RA patients
Fig. 2 Serum expression levels
of miR-146a-5p in RA patients
(before and after 3 months of
TNFi treatment) and controls
(a) and changes in miR-146-5p
expression profile in RA
patients with respect to the
presence of the C polymorphic
variant (marked in gray) of the
miR-146a-3p (rs2910164) SNP
(b)
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2004) or cardiovascular disease in patients with RA
(Lo´pez-Mejı´as et al. 2012).
Our genotyping results seem to be in agreement with
those previously published. The frequency of the del allele
was formerly reported to vary 32–54% between various
ethnic populations, compared with 42 and 39% for patients
and controls of the present study (Amador et al. 2016; Koc
et al. 2014). However, we did not find any association with
predisposition to RA. Nevertheless, we did observe some
relationships with the treatment outcome.
The ins/ins homozygosity was found to be associated
with worse response to therapy with TNFi. Interestingly, a
comparison of the differences in miR-146a serum levels
before and three months after TNFi treatment showed that
patients lacking this ins/ins homozygous genotype had over
three times higher mean difference between serum levels at
these two time points (1.748 vs 0.558 pg/mL, p = 0.093)
as compared to those carrying ins/ins homozygosity that
were characterized by similar circulating miR-146a levels.
Results from the in vitro functional study (Karban et al.
2004) suggest that the presence of the deletion may be
associated with diminished expression of the gene, leading
to reduced p50/p105 NF-jB protein production. Since p50
has been shown to repress the production of pro-inflam-
matory cytokines, including TNF-a (Pereira and Oakley
2008), beneficial role of ins genotype in context of anti-
TNF treatment outcome may be expected.
Indeed, it was observed that the presence of the del
allele enhances production of pro-inflammatory cytokines
such as, for example, IL-6 (44.23 vs 14.80 pg/mL, for del/
del vs ins/ins genotypes; Koc et al. 2014) or TNF-a (91.32
vs 66.10 vs 40.73 pg/mL, for del/del, del/ins, ins/ins
genotype carriers, respectively; our unpublished results).
However, in the present study, the ins/ins genotype
correlated with worse response to anti-TNF therapy.
Nonetheless, it should be noted that in vitro studies
involving a restricted set of biological factors may not
reflect interactions occurring in vivo in a disease environ-
ment. Furthermore, the ins variant has been previously
documented as a risk factor of other autoimmune-related
diseases such as psoriasis (Li et al. 2008) or Behcet’s
disease (Yenmis et al. 2015). Moreover, recently per-
formed meta-analysis concerning a role of the
polymorphism in autoimmune disorders revealed the
favorable effect of the del allele (Zou et al. 2011).
In summary, these preliminary results support the
hypothesis that miR-146a might be involved in pathogen-
esis of RA as differences in serum levels were observed
during therapy with TNF-a inhibitors. The results of the
present study also suggest that the miR-146a polymor-
phism may be associated with miRNA levels in serum after
anti-TNF-a treatment while the NFkB1 polymorphism may
affect the efficacy of the therapy. Obviously, these
observations should be confirmed in a more extensive
study. More research is needed to delineate the mechanism
of NF-jB and miR-146a action underlying inflammatory
response in RA.
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